Neogen Raises Guidance as Cost-Cutting Takes Hold

Dow Jones
Jan 08

By Nicholas G. Miller

 

Neogen raised its fiscal-year guidance as the company's cost-cutting and transformation initiatives begin to deliver results.

The food and animal safety company now expects fiscal-year revenue of $845 million to $855 million, up from its previous forecast of $820 million to $840 million. It also guided for adjusted earnings before interest, taxes, depreciation and amortization of $175 million, compared with its previous outlook of $165 million to $175 million.

For the second quarter, the company posted a loss of $15.9 million, or 7 cents a share, compared with a loss of $456.3 million, or $2.10 a share, the year prior.

Adjusted earnings were 10 cents a share. Analysts polled by FactSet expected 6 cents.

Revenue fell 2.8% to $224.7 million. Wall Street expected $207.8 million.

In September, the company implemented cost-cutting initiatives, including layoffs, with the aim of improving margins. The company said Thursday it was seeing progress in its transformation strategy. "While it is early in the process, and our industry is currently seeing macro headwinds, our team drove significant sequential improvement in core revenue growth and profitability in the second quarter," said Chief Executive Mike Nassif.

 

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

 

(END) Dow Jones Newswires

January 08, 2026 07:16 ET (12:16 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10